UNSPSC 41151716: Clinical toxicology control material

In this classification, a Clinical toxicology control material is a device intended to measure Clinical toxicology control material for clinical toxicology purposes. US FDA regulates Clinical toxicology control material under 21 CFR 862.3280 and under FDA product code DIF

UNSPSC 41151716 Clinical toxicology control material (Commodity) shows no relevant recent state and local procurement activity. The eight opportunities posted since late March 2026 in the tracker — spanning Mississippi State University, the City of Philadelphia, the Texas Health and Human Services Commission, the State of Oregon, the County of Santa Clara, Brazoria County, the State of Illinois, Broward County, and others — involve laboratory and analytical equipment, forensic supplies, water testing reagents, educational materials, and specialized research instrumentation, none of which align with clinical toxicology control materials as a product category. The COLILERT reagent procurement by the Texas HHSC (due July 8, 2026) represents bacteriological water-sample testing reagents rather than toxicology controls; the remaining solicitations address motion-capture systems, spectrometers, DMA instruments, nitrogen generators, fire alarm components, and similar equipment wholly outside the toxicology control material scope. State and local procurement under this code does not surface in the recent-opportunities dataset.

The code's narrow product definition—materials used to validate and quality-assure clinical toxicology assays and testing—does not appear to drive active demand through standard state and local procurement channels. Healthcare systems, public health laboratories, state forensic labs, and toxicology reference centers that would ordinarily procure such materials typically source them through standing vendor contracts, GPO affiliations, or direct relationships with manufacturers rather than through competitive RFPs, RFQs, or ITBs. Without visible recent solicitation activity, the code signals minimal portfolio opportunity at present and warrants continued monitoring rather than immediate business development focus.